Viva Biotech FY26 H1 net profit falls 32.1% to RMB 100.9 million; revenue rises 21% to RMB 1.01 billion

• VIVA Biotech Holdings posted revenue of RMB 1.01 billion, up 21% year on year, for the six months ended June 30, 2026.
• Net profit fell to RMB 100.9 million, down on lower investment income, FX losses from a weaker U.S. dollar, higher R&D spending.
• Gross profit was RMB 341.7 million; gross margin narrowed to 34% from 40.8%, as cost of sales rose faster than revenue.
• Adjusted non-IFRS net profit declined to RMB 128.3 million, reflecting lower investment gains and higher platform development costs.
• CDMO growth drove results, with a peptide project in commercial production; a small-molecule commercial project entered PPQ, targeting a 2027 launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300301), on August 26, 2026, and is solely responsible for the information contained therein.